Volume : 12, Issue : 04, April – 2025
Title:
CLOPIDOGREL MONOTHERAPY TO TREAT DOUBLE-RISK ACUTE CORONARY SYNDROME AND ALSO SHOW DIFFERENCE CLOPIDOGREL VS DAPT IN ACUTE CORONARY SYNDROMES WITH HIGH BLEEDING RISK
Authors :
Dr Uzair Aslam, Dr Tayyab Mahmood, Dr.Syed Hur Hussain Hamdani, Dr Manisha,Dr Talha Tahir, Ammar ul Hassan
Abstract :
Background: Acute Coronary Syndrome or ACS is a medical condition which includes increased risk of ischemic terminologies. This standard type of therapy often includes Dual Antiplatelet Therapy or DAPT, it comprises of aspirin and some inhibitors like P2Y12 such as clopidogrel. Moreover, that DAPT increases risk of bleeding, it includes those patients who have specially both high ischemic and bleeding risks, we also named them as double-risk patients. Some recent studies demonstrate that it is proposed of clopidogrel monotherapy which work as a potentially and conditionally safer alternative in this population.
Aims: This article aims to examine out the effectiveness and safe way of clopidogrel monotherapy in patients with double-risk or ACS patients. It compares out some terms between clopidogrel monotherapy and DAPT in those patients which includes high ischemic or poor supply of oxygen and blood and also bleeding risk issues.
Methodology: A systematic and research based studies show that meta-analysis of some randomized controlled trials and other observational studies which were collected from major medical databases and it were conducted among these patients. That data was extracted on some major and adverse cardiovascular events, other bleeding events and increased rate of mortality.
Results: Clopidogrel monotherapy was associated with some superior rates of MACE by comparing it to DAPT in selection of high-risk populations, while it is significantly reducing some major bleeding incidents. Moreover, selection criteria of patient’s and timing of therapy cessation were harsh to determine and also other determinants of clinical outcomes.
Conclusion: This Clopidogrel monotherapy presents some other workable options for double-risk of patients with ACS, it offers a balance between protection of thrombotic nerve and increased risk of bleeding. Other large-scale studies are necessary to refine patient’s selection and it optimize its therapeutic strategies.
Keywords: syndrome, therapeutic, thrombotic, nerve impulse.
Cite This Article:
Please cite this article in press Uzair Aslam et al., Clopidogrel Monotherapy To Treat Double-Risk Acute Coronary Syndrome And Also Show Difference Clopidogrel Vs Dapt In Acute Coronary Syndromes With High Bleeding Risk.,, Indo Am. J. P. Sci, 2025; 12(04).
Number of Downloads : 10
References:
1. Valgimigli, M., & Landi, A. (2024). Clopidogrel monotherapy for double-risk acute coronary syndrome. JAMA cardiology, 9(6), 532-533.
2. Li, Y., Li, J., Wang, B., Jing, Q., Zeng, Y., Hou, A., … & OPT-BIRISK Investigators. (2024). Extended clopidogrel monotherapy vs DAPT in patients with acute coronary syndromes at high ischemic and bleeding risk: the OPT-BIRISK randomized clinical trial. JAMA cardiology, 9(6), 523-531.
3. Li, X. M., Li, H. D., Shao, Y. Y., Ji, J. Z., Tang, K., Zheng, Z. D., … & Xie, H. G. (2024). The metabolic activation of and platelet response to vicagrel vary with P-glycoprotein deficiency, rather than P-glycoprotein inhibition, in mice. Xenobiotica, 54(9), 759-769.
4. Bellettini, E., & De Luca, L. (2021). Antithrombotic therapy in patients with coronary artery disease and prior stroke. Journal of Clinical Medicine, 10(9), 1923.
5. Lüscher, T. F., Davies, A., Beer, J. H., Valgimigli, M., Nienaber, C. A., Camm, J. A., … & Konstantinides, S. V. (2022). Towards personalized antithrombotic management with drugs and devices across the cardiovascular spectrum. European heart journal, 43(10), 940-958.
6. Avogaro, A., Barilla, F., Cavalot, F., Consoli, A., Federici, M., Mancone, M., … & Purrello, F. (2021). Cardiovascular risk management in type 2 diabetes mellitus: A joint position paper of the Italian Cardiology (SIC) and Italian Diabetes (SID) Societies. Nutrition, Metabolism and Cardiovascular Diseases, 31(6), 1671-1690.
7. Motovska, Z., & Montalescot, G. (2021). The Cornelian dilemma of quitting DAPT. European Heart Journal, 42(45), 4635-4637.
8. Bousser, M. G. (2009). Antithrombotic agents in the prevention of ischemic stroke. Cerebrovascular Diseases, 27.
9. Collette, C., Clerc‐Urmès, I., Laborde‐Castérot, H., Frimat, L., Ayav, C., Peters, N., … & Thilly, N. (2016). Antiplatelet and oral anticoagulant therapies in chronic hemodialysis patients: prescribing practices and bleeding risk. pharmacoepidemiology and drug safety, 25(8), 935-943.
10. Nati-Castillo, H. A., Aristizabal-Colorado, D., Ordoñez, C. L., Proaño, D. E., Ortiz-Prado, E., & Izquierdo-Condoy, J. S. (2024). Takotsubo syndrome as an acute cardiac complication following combined chemotherapy. International Journal of Cardiology Cardiovascular Risk and Prevention, 22, 200292.
11. Bellettini, E., & De Luca, L. (2021). Antithrombotic therapy in patients with coronary artery disease and prior stroke. Journal of Clinical Medicine, 10(9), 1923.
12. Arboleda, V., Hackworth, A., Bonnice, S., Gonzalez, V., Cabrera, D., Colletti, C., … & Kesselman, M. M. (2024). The role of aspirin, statins, colchicine, and IL-1 inhibitors in prevention of cardiovascular events: a systematic integrative review. Journal of Osteopathic Medicine, 124(3), 97-106.
13. Moreno, R. (2017). Antithrombotic Therapy After Transcatheter Aortic Valve Implantation. American Journal of Cardiovascular Drugs, 17(4), 265-271.
14. Avogaro, A., Barilla, F., Cavalot, F., Consoli, A., Federici, M., Mancone, M., … & Purrello, F. (2021). Cardiovascular risk management in type 2 diabetes mellitus: A joint position paper of the Italian Cardiology (SIC) and Italian Diabetes (SID) Societies. Nutrition, Metabolism and Cardiovascular Diseases, 31(6), 1671-1690.
15. Katsiki, N., Purrello, F., Tsioufis, C., & Mikhailidis, D. P. (2017). Cardiovascular disease prevention strategies for type 2 diabetes mellitus. Expert Opinion on Pharmacotherapy, 18(12), 1243-1260.
16. Yu, J. (2020). The Investigation of Bleeding Complications Following Cardiovascular Intervention (Doctoral dissertation, UNSW Sydney).
17. Erglis, A., Kalvelis, A., Lejnieks, A., Dzerve, V., Latkovskis, G., Mintale, I., … & Rasa, I. (2008). Guidelines on cardiovascular disease prevention Riga, 2007. In Seminars in Cardiovascular Medicine (Vol. 13, p. 4).
18. Mattle, K. N. H. P. (2003). Diabetes and Stroke. Cerebrovasc Dis, 15(2), 25-30.
19. Ozolina, A. (2013). INFLUENCE OF COAGULATION SYSTEM CHANGES AND GENETIC POLYMORPHISMS ON POSTOPERATIVE BLEEDING AFTER ON PUMP CARDIAC SURGERY.
20. Nedeltchev, K., & Mattle, H. P. (2003). Diabetes and Stroke. Cerebrovascular Diseases, 15.
21. Oz, M. D., Ozdemir, F., & Suzen, H. S. (2021). The influence of genetic variations and drug interactions based on metabolism of antidepressants and anticonvulsants. Current drug metabolism, 22(8), 596-627.